FINWIRES · TerminalLIVE
FINWIRES

Frontier Lithium Closes C$15 Million Bought Deal Offering

作者

-- Frontier Lithium (FL.V) closed its previously announced bought deal offering of units of the company with a syndicate of underwriters led by BMO Capital Markets, said the company on Thursday.

An aggregate of 20 million units were sold at a price of C$0.75 each for gross proceeds to the company of C$15 million, said the company.

Each unit is comprised of one common share and half of one common share purchase warrant. Each whole warrant shall be exercisable to acquire one common share at a price of C$1.00 per warrant share for a period of two years from the closing of the offering, stated the company.

A total of six insiders participated in the offering, acquiring a total of 136,668 units for gross proceeds $102,501, added the company.

The net proceeds will be used for advancing the PAK Lithium Project, said the company and added that these funds will support the completion of an updated mine and mill technical report, facilitate activities related to government-funded or cost-shared infrastructure initiatives, permitting, advancement of Lithium Conversion Study and cover general administrative as well as corporate expenses.

"This financing marks an important step in advancing the PAK Lithium Project, supporting key engineering, permitting and downstream initiatives that will continue to de-risk the asset and support the Company's efforts toward future project financing", said Trevor Walker, President and Chief Executive Officer of the company. "We were pleased to see continued support from long-term shareholders, new institutional investors and insiders, reinforcing our belief that Frontier is well positioned for the next phase of the market-supporting a secure North American lithium supply, advancing a phased de-risking strategy, and positioning the project as a strategic asset within the emerging domestic critical minerals supply chain."

The company's shares were last seen unchanged at $0.62 on the TSX Venture Exchange.

相關文章

Sectors

產業動態:消費者

週四下午,消費性股票走高,道富消費必需品精選行業SPDR ETF (XLP)上漲1.4%,道富非必需消費品精選行業SPDR ETF (XLY)上漲0.4%。 公司方面,蘭姆韋斯頓(LW)股價上漲1.6%,此前股東Starboard Value週四致信董事會,表示公司應召開投資者日活動,並將盈利預期調整至正常水平。

$LW
Research

研究快訊:CFRA維持對Firstenergy Corp.股票的買進評等。

獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下:我們將12個月目標股價下調1美元至55美元,本益比為20倍,基於未來12個月每股收益預期2.75美元,高於五年平均15.6倍。我們將2026年每股收益預期下修0.02美元至2.72美元,並將2027年每股收益預期下修0.01美元至2.93美元。第一季核心每股收益年增7.5%,打破了先前連續三個季度下滑的局面,我們預計在整個預測期內,成長動能將持續。 我們觀察到資料中心需求呈現正面趨勢,長期合約需求(4.3 GW)自 2026 年 2 月(4.1 GW)以來成長了 4%,自 2025 年 2 月(2.9 GW)以來成長了 47%;同時,在建專案需求(14.9 GW)自 2026 年 2012 年 125%, 2 月(6.1 GW)以來增長了一倍以上。自 2022 年以來,FE 已將基礎維運成本降低了 2 億美元以上(15%),預計 2026 年第一季將年比進一步下降約 5%,同時可靠性指標也得到提升。我們認為,FE 的成本控制、服務品質的提升以及具有競爭力的價格定位,將轉化為更有利的費率調整結果、更低的拒付風險以及更高的潛在淨資產收益率 (ROE)。

$FE
Australia

市場動態:FDA專家小組投票反對阿斯特捷利康乳癌藥物的益處

根據彭博社週四報道,美國食品藥物管理局(FDA)腫瘤藥物諮詢委員會否決了阿斯特捷利康(AZN)用於治療乳癌的候選藥物卡美司群(Camizestrant)的療效。 彭博社稱,六名委員會成員投票反對該藥物,因為他們對試驗設計及其在臨床應用中的潛在影響存在分歧。 根據一份簡報文件,該藥物試驗達到了無惡化存活期(PFS)的主要終點以及無惡化存活期2(PFS2)終點,但FDA認為PFS2不適合作為監管決策的終點。 (市場動態新聞來自與全球市場專業人士的對話。這些資訊據信來自可靠來源,但可能包含傳聞和推測。準確性無法保證。)Price: $189.60, Change: $+4.40, Percent Change: +2.37%

$AZN